Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

  • Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine
  • Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation
  • The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications

Earlier this month, a Time magazine article reported on the “new era” of psychedelic medicine ( On the leading edge of this collective breakthrough is Cybin (NEO: CYBN) (NYSE American: CYBN), a company focused on progressing psychedelic therapeutics, addressing the mental health crisis and transforming the treatment landscape. As part of its mission, the company has filed an international patent application related to delivery methods of psychedelic medications ( 

“As a growing number of states and cities move to decriminalize drugs, and investors flock to an emerging market for psychedelic health care, substances like psilocybin, ketamine and LSD are edging into mainstream culture—and setting the stage for a paradigm shift in modern medicine,” stated the Time article.  “Within the next few years, we could see psychedelic therapies prescribed for refractory depression and post-traumatic stress disorder (‘PTSD’), or used in palliative care among those facing a life-limiting illness. . . . It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care.”

Committed to finding answers to the growing need for effective mental health care solutions, Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation as well as devices for performing those methods.

The application, which is governed by the Patent Cooperation Treaty (“PCT”), would give Cybin potential to obtain patent coverage in 153 countries.

“The continued progression of our research programs guides our discovery of new molecules and differentiating treatment approaches,” said Cybin CEO Doug Drysdale. “Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading innovator in the development of putative psychedelic treatments for a variety of mental health conditions.”

Based on its research and study, Cybin is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications. Traditional oral drug administration presents certain challenges that CYBN believes can be alleviated through inhalation of the psychedelic substance. Specifically, the company reports, it expects inhalation delivery to facilitate optimized psychedelic session timing compared to oral administration of the same compounds, lower doses of psychedelic therapeutics while preserving efficacy, and providing health care providers with more control during psychedelic sessions.

The patent was filed in support of Cybin’s CYB004 preclinical development program. The patent would increase the company’s library of drug-delivery modalities focused on optimal delivery of psychedelics and strengthen Cybin’s growing IP portfolio. The filing also includes support for future research programs the company may undertake, including those exploring various ways to reduce or minimize negative side effects in psychedelic psychotherapy patients. The company may also look at ways to lower medication doses without impacting treatment efficacy while increasing the long-term efficacy of psychedelic sessions.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at 

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050